Compare Regeneron Pharmaceuticals Inc (REGN) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Standard Lithium Ltd — how do they compare? Regeneron Pharmaceuticals Inc trades at $745.91 (market cap $76.14B), while Standard Lithium Ltd trades at $1.61 (market cap $398.07M). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 191.3× Standard Lithium Ltd's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Standard Lithium Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Standard Lithium Ltd for 23 Days on average.
| REGN | SLI | |
|---|---|---|
Market Cap | $76.14B | $398.07M |
Volume | 500,239 | 1,564,155 |
Sector | Health | Basic Materials |
52-Week High | $852.03 | $5.65 |
52-Week Low | $557.73 | $1.61 |
Typical Hold Time | 107 Days | 23 Days |
Enterprise Value | $70.85B | $260.98M |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $747.21, up 0.69% with strong recent earnings beats. The stock shows bearish technical signals but maintains robust fundamentals with 84.86% gross margins and consistent revenue growth. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, providing significant upfront and milestone payments. Analyst consensus remains strongly bullish with 69% buy ratings and an $849.84 price target, representing 13.7% upside potential from current levels.
REGN presents a compelling growth story with strong profitability and strategic partnerships, though technical indicators suggest near-term consolidation. The expanded Sanofi collaboration and promising clinical trial data provide catalysts, while competition in key therapeutic areas and reliance on blockbuster drugs represent ongoing risks. Wall Street optimism remains high given the company's execution track record and pipeline potential.
SLI trades at $1.625, down 1.52% today, with a bearish technical signal despite bullish oscillators. The company shows negative profitability with ROE at -15.55% and no revenue in 2025, but has beaten EPS estimates in recent quarters. Key developments include progress toward a 2026 final investment decision for its Arkansas lithium project and new offtake agreements.
SLI presents high risk with no current revenue and negative cash flow from operations, but significant upside potential exists if its lithium projects advance. The consensus price target of $3.83 implies 136% upside, supported by 100% buy ratings from analysts. Execution risk on project timelines and funding remains the primary concern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
